Allianz Group reports strong financial performance and sustainability leadership in 2024

Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) Allianz SE
Oliver Bäte Chairman of the Board of Management of Allianz SE (CEO) - Allianz SE
0Comments

The Allianz Group, a global insurer and asset manager, operates in nearly 70 countries. The company provides a wide range of insurance products and services to both private individuals and businesses, including property, life, health, assistance, credit insurance, and global business coverage.

Allianz also manages significant assets on behalf of its clients. As of June 30, 2025, the group managed approximately 749 billion euros for its insurance customers. In addition to this, its asset management divisions—PIMCO and Allianz Global Investors—oversee about 1.8 trillion euros in third-party assets.

The company has integrated ecological and social criteria into its business operations and investment decisions. This approach has helped Allianz secure a leading position in the Dow Jones Sustainability Index within the insurance sector.

In 2024, Allianz employed more than 156,000 people worldwide. The group reported a total business volume of 179.8 billion euros and an operating profit of 16.0 billion euros for that year.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.